{"pmid":32338298,"title":"The After Diagnosis Head and Neck cancer-specific Patient Concerns Inventory (HaNC-AD) as a pre-treatment preparation aid during the COVID-19 pandemic.","text":["The After Diagnosis Head and Neck cancer-specific Patient Concerns Inventory (HaNC-AD) as a pre-treatment preparation aid during the COVID-19 pandemic.","The coronavirus disease 2019 pandemic has resulted in new challenges for clinicians, head and neck cancer (HNC) patients and carers. There is evidence that the current crisis is affecting the management of HNC patients. Most healthcare systems have introduced remote consultations to decrease the risk of coronavirus infection to patients, carers and clinicians. At present, HNC patients may be anxious and due to logistical issues, may not be adequately prepared for their treatment. To ensure that patients have a thorough understanding of their treatment and expected outcome during the current COVID-19 crisis there may be merit in the use of the HaNC-AD PCI.","Eur Arch Otorhinolaryngol","Kanatas, Anastasios","Rogers, S N","32338298"],"abstract":["The coronavirus disease 2019 pandemic has resulted in new challenges for clinicians, head and neck cancer (HNC) patients and carers. There is evidence that the current crisis is affecting the management of HNC patients. Most healthcare systems have introduced remote consultations to decrease the risk of coronavirus infection to patients, carers and clinicians. At present, HNC patients may be anxious and due to logistical issues, may not be adequately prepared for their treatment. To ensure that patients have a thorough understanding of their treatment and expected outcome during the current COVID-19 crisis there may be merit in the use of the HaNC-AD PCI."],"journal":"Eur Arch Otorhinolaryngol","authors":["Kanatas, Anastasios","Rogers, S N"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32338298","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1007/s00405-020-05995-9","keywords":["coronavirus","head and neck cancer","patient concerns inventory","sars-cov-2"],"topics":["Prevention"],"weight":1,"_version_":1665264685576880128,"score":8.574329,"similar":[{"pmid":32330858,"title":"Head and neck oncology during the COVID-19 pandemic: Reconsidering traditional treatment paradigms in light of new surgical and other multilevel risks.","text":["Head and neck oncology during the COVID-19 pandemic: Reconsidering traditional treatment paradigms in light of new surgical and other multilevel risks.","The COVID-19 pandemic demands reassessment of head and neck oncology treatment paradigms. Head and neck cancer (HNC) patients are generally at high-risk for COVID-19 infection and severe adverse outcomes. Further, there are new, multilevel COVID-19-specific risks to patients, surgeons, health care workers (HCWs), institutions and society. Urgent guidance in the delivery of safe, quality head and neck oncologic care is needed. Novel barriers to safe HNC surgery include: (1) imperfect presurgical screening for COVID-19; (2) prolonged SARS-CoV-2 aerosolization; (3) occurrence of multiple, potentially lengthy, aerosol generating procedures (AGPs) within a single surgery; (4) potential incompatibility of enhanced personal protective equipment (PPE) with routine operative equipment; (5) existential or anticipated PPE shortages. Additionally, novel, COVID-19-specific multilevel risks to HNC patients, HCWs and institutions, and society include: use of immunosuppressive therapy, nosocomial COVID-19 transmission, institutional COVID-19 outbreaks, and, at some locations, societal resource deficiencies requiring health care rationing. Traditional head and neck oncology doctrines require reassessment given the extraordinary COVID-19-specific risks of surgery. Emergent, comprehensive management of these novel, multilevel surgical risks are needed. Until these risks are managed, we temporarily favor nonsurgical therapy over surgery for most mucosal squamous cell carcinomas, wherein surgery and nonsurgical therapy are both first-line options. Where surgery is traditionally preferred, we recommend multidisciplinary evaluation of multilevel surgical-risks, discussion of possible alternative nonsurgical therapies and shared-decision-making with the patient. Where surgery remains indicated, we recommend judicious preoperative planning and development of COVID-19-specific perioperative protocols to maximize the safety and quality of surgical and oncologic care.","Oral Oncol","Day, Andrew T","Sher, David J","Lee, Rebecca C","Truelson, John M","Myers, Larry L","Sumer, Baran D","Stankova, Lenka","Tillman, Brittny N","Hughes, Randall S","Khan, Saad A","Gordin, Eli A","32330858"],"abstract":["The COVID-19 pandemic demands reassessment of head and neck oncology treatment paradigms. Head and neck cancer (HNC) patients are generally at high-risk for COVID-19 infection and severe adverse outcomes. Further, there are new, multilevel COVID-19-specific risks to patients, surgeons, health care workers (HCWs), institutions and society. Urgent guidance in the delivery of safe, quality head and neck oncologic care is needed. Novel barriers to safe HNC surgery include: (1) imperfect presurgical screening for COVID-19; (2) prolonged SARS-CoV-2 aerosolization; (3) occurrence of multiple, potentially lengthy, aerosol generating procedures (AGPs) within a single surgery; (4) potential incompatibility of enhanced personal protective equipment (PPE) with routine operative equipment; (5) existential or anticipated PPE shortages. Additionally, novel, COVID-19-specific multilevel risks to HNC patients, HCWs and institutions, and society include: use of immunosuppressive therapy, nosocomial COVID-19 transmission, institutional COVID-19 outbreaks, and, at some locations, societal resource deficiencies requiring health care rationing. Traditional head and neck oncology doctrines require reassessment given the extraordinary COVID-19-specific risks of surgery. Emergent, comprehensive management of these novel, multilevel surgical risks are needed. Until these risks are managed, we temporarily favor nonsurgical therapy over surgery for most mucosal squamous cell carcinomas, wherein surgery and nonsurgical therapy are both first-line options. Where surgery is traditionally preferred, we recommend multidisciplinary evaluation of multilevel surgical-risks, discussion of possible alternative nonsurgical therapies and shared-decision-making with the patient. Where surgery remains indicated, we recommend judicious preoperative planning and development of COVID-19-specific perioperative protocols to maximize the safety and quality of surgical and oncologic care."],"journal":"Oral Oncol","authors":["Day, Andrew T","Sher, David J","Lee, Rebecca C","Truelson, John M","Myers, Larry L","Sumer, Baran D","Stankova, Lenka","Tillman, Brittny N","Hughes, Randall S","Khan, Saad A","Gordin, Eli A"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330858","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.oraloncology.2020.104684","keywords":["covid-19 pandemic","head and neck cancer","head and neck oncology","mucosal squamous cell carcinoma","multilevel risk","risk stratification","sars-cov-2","surgical barriers","surgical risk","treatment paradigms"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664996914956861440,"score":410.11932},{"pmid":32329923,"title":"Early Institutional Head and Neck Oncologic and Microvascular Surgery Practice Patterns Across the United States During the SARS-CoV-2 (COVID19) Pandemic.","text":["Early Institutional Head and Neck Oncologic and Microvascular Surgery Practice Patterns Across the United States During the SARS-CoV-2 (COVID19) Pandemic.","BACKGROUND: The SARS-CoV-2 (COVID-19) pandemic has caused rapid changes in head and neck cancer (HNC) care. \"Real-time\" methods to monitor practice patterns can optimize provider safety and patient care. METHODS: Head and neck surgeons from 14 institutions in the United States regularly contributed their practice patterns to a shared spreadsheet. Data from March 27th, 2020 to April fifth, 2020 was analyzed. RESULTS: All institutions had significantly restricted HNC clinic evaluations. 2 institutions stopped free flap surgery with the remaining scheduling surgery by committee review. Factors contributing to reduced clinical volume included lack of personal protective equipment (PPE) (35%) and lack of rapid COVID-19 testing (86%). CONCLUSIONS: The COVID-19 pandemic has caused a reduction in HNC care. Rapid COVID-19 testing and correlation with infectious potential remain paramount to resuming the care of head and neck cancer patients. Cloud-based platforms to share practice patterns will be essential as the pandemic evolves.","Head Neck","Patel, Rusha J","Kejner, Alexandra","McMullen, Caitlin","32329923"],"abstract":["BACKGROUND: The SARS-CoV-2 (COVID-19) pandemic has caused rapid changes in head and neck cancer (HNC) care. \"Real-time\" methods to monitor practice patterns can optimize provider safety and patient care. METHODS: Head and neck surgeons from 14 institutions in the United States regularly contributed their practice patterns to a shared spreadsheet. Data from March 27th, 2020 to April fifth, 2020 was analyzed. RESULTS: All institutions had significantly restricted HNC clinic evaluations. 2 institutions stopped free flap surgery with the remaining scheduling surgery by committee review. Factors contributing to reduced clinical volume included lack of personal protective equipment (PPE) (35%) and lack of rapid COVID-19 testing (86%). CONCLUSIONS: The COVID-19 pandemic has caused a reduction in HNC care. Rapid COVID-19 testing and correlation with infectious potential remain paramount to resuming the care of head and neck cancer patients. Cloud-based platforms to share practice patterns will be essential as the pandemic evolves."],"journal":"Head Neck","authors":["Patel, Rusha J","Kejner, Alexandra","McMullen, Caitlin"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32329923","week":"202017|Apr 20 - Apr 26","doi":"10.1002/hed.26189","keywords":["covid-19 pandemic","head and neck cancer treatment","head and neck surgery","microvascular reconstruction","practice patterns"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["United States","United States"],"countries":["United States"],"countries_codes":["USA|United States"],"_version_":1664996914945327106,"score":345.67096},{"pmid":32302681,"title":"Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: an ASTRO-ESTRO consensus statement.","text":["Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: an ASTRO-ESTRO consensus statement.","INTRODUCTION: Due to the unprecedented disruption of health care services by the COVID-19 pandemic, the American Society of Radiation Oncology (ASTRO) and the European Society for Radiotherapy and Oncology (ESTRO) identified an urgent need to issue practice recommendations for radiation oncologists treating head and neck cancer (HNC), in a time of heightened risk for patients and staff, and of limited resources. METHODS: A panel of international experts from ASTRO, ESTRO and select Asia-Pacific countries completed a modified rapid Delphi process. Questions and topics were presented to the group, and subsequent questions developed from iterative feedback. Each survey was open online for 24 hours, and successive rounds started within 24 hours of the previous round. The chosen cutoffs for strong agreement (>/=80%) and agreement (>/=66%) were extrapolated from the RAND methodology. Two pandemic scenarios: early (risk mitigation) and late (severely reduced radiotherapy resources) were evaluated. The panel developed treatment recommendations for five HNC cases. RESULTS: In total, 29/31 (94%) of those invited accepted, and after a replacement 30/30 completed all three surveys (100% response rate). There was agreement or strong agreement across a number of practice areas including: treatment prioritisation, whether to delay initiation or interrupt radiotherapy for intercurrent SARS-CoV-2 infection, approaches to treatment (radiation dose-fractionation schedules and use of chemotherapy in each pandemic scenario), management of surgical cases in event of operating room closures, and recommended adjustments to outpatient clinic appointments and supportive care. CONCLUSIONS: This urgent practice recommendation was issued in the knowledge of the very difficult circumstances in which our patients find themselves at present, navigating strained health care systems functioning with limited resources and at heightened risk to their health during the COVID-19 pandemic. The aim of this consensus statement is to ensure high-quality HNC treatments continue, to save lives and for symptomatic benefit.","Int J Radiat Oncol Biol Phys","Thomson, David J","Palma, David","Guckenberger, Matthias","Balermpas, Panagiotis","Beitler, Jonathan J","Blanchard, Pierre","Brizel, David","Budach, Wilfred","Caudell, Jimmy","Corry, June","Corvo, Renzo","Evans, Mererid","Garden, Adam S","Giralt, Jordi","Gregoire, Vincent","Harari, Paul M","Harrington, Kevin","Hitchcock, Ying J","Johansen, Jorgen","Kaanders, Johannes","Koyfman, Shlomo","Langendijk, J A","Le, Quynh-Thu","Lee, Nancy","Margalit, Danielle","Mierzwa, Michelle","Porceddu, Sandro","Soong, Yoke Lim","Sun, Ying","Thariat, Juliette","Waldron, John","Yom, Sue S","32302681"],"abstract":["INTRODUCTION: Due to the unprecedented disruption of health care services by the COVID-19 pandemic, the American Society of Radiation Oncology (ASTRO) and the European Society for Radiotherapy and Oncology (ESTRO) identified an urgent need to issue practice recommendations for radiation oncologists treating head and neck cancer (HNC), in a time of heightened risk for patients and staff, and of limited resources. METHODS: A panel of international experts from ASTRO, ESTRO and select Asia-Pacific countries completed a modified rapid Delphi process. Questions and topics were presented to the group, and subsequent questions developed from iterative feedback. Each survey was open online for 24 hours, and successive rounds started within 24 hours of the previous round. The chosen cutoffs for strong agreement (>/=80%) and agreement (>/=66%) were extrapolated from the RAND methodology. Two pandemic scenarios: early (risk mitigation) and late (severely reduced radiotherapy resources) were evaluated. The panel developed treatment recommendations for five HNC cases. RESULTS: In total, 29/31 (94%) of those invited accepted, and after a replacement 30/30 completed all three surveys (100% response rate). There was agreement or strong agreement across a number of practice areas including: treatment prioritisation, whether to delay initiation or interrupt radiotherapy for intercurrent SARS-CoV-2 infection, approaches to treatment (radiation dose-fractionation schedules and use of chemotherapy in each pandemic scenario), management of surgical cases in event of operating room closures, and recommended adjustments to outpatient clinic appointments and supportive care. CONCLUSIONS: This urgent practice recommendation was issued in the knowledge of the very difficult circumstances in which our patients find themselves at present, navigating strained health care systems functioning with limited resources and at heightened risk to their health during the COVID-19 pandemic. The aim of this consensus statement is to ensure high-quality HNC treatments continue, to save lives and for symptomatic benefit."],"journal":"Int J Radiat Oncol Biol Phys","authors":["Thomson, David J","Palma, David","Guckenberger, Matthias","Balermpas, Panagiotis","Beitler, Jonathan J","Blanchard, Pierre","Brizel, David","Budach, Wilfred","Caudell, Jimmy","Corry, June","Corvo, Renzo","Evans, Mererid","Garden, Adam S","Giralt, Jordi","Gregoire, Vincent","Harari, Paul M","Harrington, Kevin","Hitchcock, Ying J","Johansen, Jorgen","Kaanders, Johannes","Koyfman, Shlomo","Langendijk, J A","Le, Quynh-Thu","Lee, Nancy","Margalit, Danielle","Mierzwa, Michelle","Porceddu, Sandro","Soong, Yoke Lim","Sun, Ying","Thariat, Juliette","Waldron, John","Yom, Sue S"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302681","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.ijrobp.2020.04.016","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664635401412804608,"score":342.8136},{"pmid":32312163,"title":"Impact of the COVID-19 Pandemic on the Management of Head and Neck Malignancies.","text":["Impact of the COVID-19 Pandemic on the Management of Head and Neck Malignancies.","The impact of the coronavirus disease 2019 (COVID-19) pandemic on the management of head and neck cancer must be addressed. Immediate measures to reduce transmission rates and protect patients and providers take priority and necessitate some delays in care, particularly for patients with mild symptoms or less aggressive cancers. However, strict guidelines have yet to be developed, and many unintentional delays in care are to be expected based on the magnitude of the looming public health crisis. The medical complexity of head and neck cancer management may lead to prolonged delays that worsen treatment outcomes. Therefore, those caring for patients with head and neck cancer must take action to reduce these negative impacts as the country rallies to overcome the challenges posed by this pandemic.","Otolaryngol Head Neck Surg","Werner, Michael T","Carey, Ryan M","Albergotti, W Greer","Lukens, John N","Brody, Robert M","32312163"],"abstract":["The impact of the coronavirus disease 2019 (COVID-19) pandemic on the management of head and neck cancer must be addressed. Immediate measures to reduce transmission rates and protect patients and providers take priority and necessitate some delays in care, particularly for patients with mild symptoms or less aggressive cancers. However, strict guidelines have yet to be developed, and many unintentional delays in care are to be expected based on the magnitude of the looming public health crisis. The medical complexity of head and neck cancer management may lead to prolonged delays that worsen treatment outcomes. Therefore, those caring for patients with head and neck cancer must take action to reduce these negative impacts as the country rallies to overcome the challenges posed by this pandemic."],"journal":"Otolaryngol Head Neck Surg","authors":["Werner, Michael T","Carey, Ryan M","Albergotti, W Greer","Lukens, John N","Brody, Robert M"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32312163","week":"202017|Apr 20 - Apr 26","doi":"10.1177/0194599820921413","keywords":["covid-19","sars-cov-2","head and neck cancer"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664714520185012224,"score":316.85678},{"pmid":32303485,"pmcid":"PMC7151337","title":"French consensus on management of head and neck cancer surgery during COVID-19 pandemic.","text":["French consensus on management of head and neck cancer surgery during COVID-19 pandemic.","In the context of the current pandemic, there is a need for specific advice concerning treatment of patients with Head and Neck cancers. The rule is to limit as much as possible the number of patients in order to reduce the risks of contamination by the SARS-Cov-2 virus for both patients and the caregivers, who are particularly exposed in ENT. The aim is to minimize the risk of loss of opportunity for patients and to anticipate the increased number of cancer patients to be treated at the end of the pandemic, taking into account the degree of urgency, the difficulty of the surgery, the risk of contaminating the caregivers (tracheotomy) and the local situation (whether or not the hospital and intensive care departments are overstretched).","Eur Ann Otorhinolaryngol Head Neck Dis","Fakhry, N","Schultz, P","Moriniere, S","Breuskin, I","Bozec, A","Vergez, S","de Garbory, L","Hartl, D","Temam, S","Lescanne, E","Couloigner, V","Barry, B","32303485"],"abstract":["In the context of the current pandemic, there is a need for specific advice concerning treatment of patients with Head and Neck cancers. The rule is to limit as much as possible the number of patients in order to reduce the risks of contamination by the SARS-Cov-2 virus for both patients and the caregivers, who are particularly exposed in ENT. The aim is to minimize the risk of loss of opportunity for patients and to anticipate the increased number of cancer patients to be treated at the end of the pandemic, taking into account the degree of urgency, the difficulty of the surgery, the risk of contaminating the caregivers (tracheotomy) and the local situation (whether or not the hospital and intensive care departments are overstretched)."],"journal":"Eur Ann Otorhinolaryngol Head Neck Dis","authors":["Fakhry, N","Schultz, P","Moriniere, S","Breuskin, I","Bozec, A","Vergez, S","de Garbory, L","Hartl, D","Temam, S","Lescanne, E","Couloigner, V","Barry, B"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32303485","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.anorl.2020.04.008","keywords":["covid","covid-19","ent","head and neck cancer","sars-cov-2"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["French"],"countries":["France"],"countries_codes":["FRA|France"],"_version_":1664632934659784704,"score":309.64313}]}